Evolving Drug Classes Expand Treatment Options Across Hematologic Malignancies
Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents can lead to spleen and symptom burden reductions.
Memorial Sloan Kettering Cancer Center New York United States Prioty Islam Raajitk Rampal Alexanderp Boardman
Source: onclive.com